American Journal of Epidemiology Vol. 143, No. 7: 733-742
Copyright © 1996 by The Johns Hopkins University School of Hygiene and Public Health
other |
Trends in Human Immunodeficiency Virus Seroprevalence among Injection Drug Users Entering Drug Treatment Centers, United States, 1988–1993
1Division of HIV/AIDS, Centers for Disease Control and Prevention Atlanta, GA
2International Health Program Office, Centers for Disease Control and Prevention Atlanta, GA
Reprint requests to Dr. D. Rebecca Prevots, National Immunization Program, Mailstop E61, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333.
National unlinked sentinel surveillance data were used to describe trends in prevalent human immunodeficiency virus infection among injection drug users entering drug treatment programs in the United States from 1988 through 1993. During this 6-year period, unlinked testing was performed on 70,882 specimens from injection drug users at 60 sentinel sites. The annual change in seroprevalence was estimated for each site by odds ratios obtained from logistic regression models fit within site-specific age and race/ethnicity subgroups. Overall trends for age and race/ethnicity subgroups across sites were described by summary odds ratios calculated using the inverse variance method. A decrease was observed among younger (age less than 30 years) whites both in areas with high (10% or higher) and low (less than 10%) prevalence, although this decrease was significant only in high-prevalence areas (odds ratio = 0.90, 95% confidence interval 0.81–0.99). Seroprevalence also decreased among older whites in high-prevalence areas, although this decrease was not significant (odds ratio = 0.95, 95% confidence interval 0.89–1.00). Seroprevalence remained stable among all other age and race/ethnicity subgroups. Stable seroprevalence among the dynamic population of injection drug users entering treatment suggests continued transmission among these individuals in both high- and low-prevalence areas of the United States.
acquired immunodeficiency syndrome; HIV seroprevalence; HIV-1 substance abuse; intravenous
3Present address: National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. Lazzarini, P. Case, and C. J. Thomas A walk in the park: a case study in research ethics. J. Law Med. Ethics, March 1, 2009; 37(1): 93 - 103. [PDF]
|
|
|
|
 |
|
 G. M. McClelland, L. A. Teplin, K. M. Abram, and N. Jacobs HIV and AIDS Risk Behaviors Among Female Jail Detainees: Implications for Public Health Policy Am J Public Health, May 1, 2002; 92(5): 818 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Murrill, H. Weeks, B. C. Castrucci, H. S. Weinstock, B. P. Bell, C. Spruill, and M. Gwinn Age-Specific Seroprevalence of HIV, Hepatitis B Virus, and Hepatitis C Virus Infection Among Injection Drug Users Admitted to Drug Treatment in 6 US Cities Am J Public Health, March 1, 2002; 92(3): 385 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. BARNES, Z. YANG, J. M. POGODA, S. PRESTON-MARTIN, B. E. JONES, M. OTAYA, L. KNOWLES, S. HARVEY, K. D. EISENACH, and M. DONALD CAVE Foci of Tuberculosis Transmission in Central Los Angeles Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): 1081 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. O. Gostin, Z. Lazzarini, T. S. Jones, and K. Flaherty Prevention of HIV/AIDS and Other Blood-Borne Diseases Among Injection Drug Users: A National Survey on the Regulation of Syringes and Needles JAMA, January 1, 1997; 277(1): 53 - 62. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Karon, P. S. Rosenberg, G. McQuillan, M. Khare, M. Gwinn, and L. R. Petersen Prevalence of HIV Infection in the United States, 1984 to 1992 JAMA, July 10, 1996; 276(2): 126 - 131. [Abstract] [PDF]
|
|
|
|
|
|
AIDS Associated With Injecting-Drug Use-- United States, 1995 JAMA, June 5, 1996; 275(21): 1628 - 1629. [PDF]
|
|